权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Comprehensive Study of Carcinogemesis and Molecular Target Therapy in Thyroid Cancer

甲状腺癌致癌与分子靶向治疗的综合研究

基本信息

批准号：
15390295
负责人：
NAMBA Hiroyuki
金额：
$ 8.64万
依托单位：
Nagasaki University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2003
资助国家：
日本
起止时间：
2003 至 2005
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15390295/
关键词：
Radiation Thyroid cancer International Medical Care Molecular Epidemiology Chernobyl Transgenic mice Cancer stem cell 分子機構 BRAF ret PTC

项目摘要

It has been passed 20 years after Chernobyl nuclear power plant accident. Incidence of thyroid cancer was increased in children living contaminated area 5 years after the accident. The number of thyroid cancer still increase. According the information of Chernobyl Forum co-hosted IAEA and WHO in Vienna September 2005, total number of childhood thyroid cancer is 4,000 cases and 9 cases died among them. The disease is relatively good prognosis, however, it seemed that 20% of patients will have recurrence or metastasis to distant organs such as lung and bone. It is necessary to develop the new therapeutic remedy for the disease that is difficult for treat by conventional therapies. In this study, we performed studies to develop a new diagnostic method that discriminates malignant tumors benign that is prone to metastasize to distant organs by microarray analysis. We, further, carried on the basic studies for molecular target drugs such as Glivec, a c-ABL inhibitor, and DHMEQ, a NF-kB inhibitor to anaplastic thyroid cancer. We reported that these drugs were significantly efficient anaplastic thyroid cancers both in vitro and in vivo experiments. To enhance the therapeutic effect, we are, now, investigating cancer stem cells that seem to be real target of cancer therapy in thyroid cancer. We hope to continue to translational research in this field until establishment of good diagnostic and therapeutic tools.

切尔诺贝利核电站事故已经过去20年了。事故发生5年后，生活在污染地区的儿童甲状腺癌发病率有所增加。甲状腺癌的数量仍在增加。据国际原子能机构和世界卫生组织2005年9月在维也纳共同主办的切尔诺贝利论坛统计，儿童甲状腺癌总数为4000例，其中9例死亡。该病的预后相对较好，然而，似乎有20%的患者会出现复发或转移至肺、骨等远处器官。对于传统疗法难以治疗的疾病，有必要开发新的治疗药物。在这项研究中，我们进行了研究，开发一种新的诊断方法，通过微阵列分析区分容易转移到远处器官的良性恶性肿瘤。进一步开展了c-ABL抑制剂格列卫、甲状腺未分化癌NF-kB抑制剂DHMEQ等分子靶向药物的基础研究。我们报告说，这些药物在体外和体内实验中对甲状腺未分化癌均显着有效。为了增强治疗效果，我们现在正在研究癌症干细胞，这似乎是甲状腺癌癌症治疗的真正目标。我们希望继续在这一领域进行转化研究，直到建立良好的诊断和治疗工具。